Global Epigenetics Market Overview
Epigenetics Market Size was valued at USD2.85 Billion in 2023. The Global Epigenetics industry is projected to grow from USD 3.011 Billion in 2024 to USD 5.34 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 19.34 % during the forecast period (2024 - 2032).
Epigenetics is the study of heritable changes in gene function not involving changes in the DNA sequence such as changes in a chromosome, phenotypic affecting gene activity and expression. The sources of heritable changes may be external from environmental factors, or internal factors such as age, disease and others. Examples of Epigenetics are DNA methylation and histone modification, which alters genes expression without altering the DNA sequence.
The drivers of epigenetics market are growing risk factors and the associated increase in cases of cancer, increase in the R&D activities, developing pharmaceutical, and biotechnology sectors, application expanse of epigenetics and others. The development of high sensitive and selective tests, instrumentation and a concurrent rise in computational power is driving a massive adoption. The advancements such as the development of DNA and RNA modifying enzymes such as acetylases, methyltransferases, reverse transcriptase, ligases, and other protein-modifying enzymes has generated tremendous enthusiasm and concurrent faster market adoption.
The growing government support for biotechnology and growing partnership between academia and industry is another driver of growth. Attractive and critical advantages of technology exemplified by high-throughput molecular analysis of tissues, such as quick, cost-effective, efficient for less labor intensive and requires a lesser number of steps are the operational and economic driving factors of the epigenetics market. Other technological developments include automation, advances in PCR technology, strategic and cross-functional nature of the molecular diagnostic technology and others.
High growth of biotech and growing number of start-ups are driving the development of proprietary technology. According to national venture capital association, the Biotechnology industry received the second largest amount of venture capital for the year 2016 and ended with a 17% rise in dollars as compared with the previous year.
The prime market constraints include prohibitive costs of molecular diagnostics, ha high cost of manufacturing, consolidated nature of the market has put a premium on the price other f the epigenetics products, nascent stage of technology and high power of firms relative to buyers.
Epigenetics Market Segment Insights
The epigenetics market is segmented based on instruments, consumables, applications, technology, end users, and regions.
Epigenetics Instruments Insights
Based on instruments, the market comprises of NGS, spectrometer, PCR, software solutions and others.
Epigenetics Consumables Insights
Based on consumables, the market comprises of kit, enzymes, reagent, and others.
Epigenetics Application Insights
Based on application, the market comprises of oncology, developmental biology, drug discovery, cardiology, immunology, and others.
Epigenetics Technology Insights
Based on technology, the market comprises of methylation, histone modification, and others.
Epigenetics End-Users Insights
Based on end users the market is segmented into academia and research, pharmaceutical and biotechnology industry and others.
Epigenetics Market Regional Insights
Based on the regions, the market is segmented as North America, Europe, Asia Pacific Middle East and Africa and rest of the world.
North America is the largest market in 2016 with the U.S. in the lead position owing to the faster uptake of technology, the gigantic biotech industry of the U.S., the presence of global and technology players, which is propelling the molecular diagnostics industry.
Europe led by Germany, U.K., and France accounts for the second-largest and second fastest market during the forecasted period. Asia is anticipated to expand at the most rapid rate led by Japan, China, South Korea and India.
The Middle East and Africa market are anticipated to generate a moderate growth on account of the impoverished industry landscape and low demand due to weak economic conditions.
Key Vendors Operating In Epigenetics Market:
Some of the dominant vendors operating in the report are
- Bio-Rad (US)
- Illumina (US)
- QIAGEN (Netherlands)
- Thermo Fisher (US)
- Active Motif (US)
- Diagenode (Belgium)
- Agilent (US)
- Merck Millipore (US)
- Abcam (UK)
- New England Biolabs (US)
- PerkinElmer (US)
- Zymo Research (US).
Intended Audience
- Global epigenetics providers, manufacturers & suppliers
- Research and development (R&D) companies
- Market research and consulting service providers
- Academic institutes and universities
Report Attribute/Metric |
Details |
Market Size |
USD 5.34 Billion |
CAGR |
19.34% |
Base Year |
2023 |
Forecast Period |
2024-2032 |
Historical Data |
2020 |
Forecast Units |
Value (USD Billion) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
Instruments, Consumables, Application, Technology And End Users |
Geographies Covered |
North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors |
Bio-Rad (US), Illumina (US), QIAGEN (Netherlands), Thermo Fisher (US), Active Motif (US), Diagenode (Belgium), Agilent (US), Merck Millipore (US), Abcam (UK), New England Biolabs (US), PerkinElmer (US), Zymo Research (US) |
Frequently Asked Questions (FAQ) :
Epigenetics is the study of heritable changes in gene expression that do not involve changes to the underlying DNA sequence.
Leading players in the Epigenetics Market include Illumina, Bio-Rad, and Thermo Fisher, among others.
Growing government support for advancements in biotechnology is the major driver for the Epigenetics Market.
North America is the largest regional market for epigenetics.
Major applications of epigenetics include oncology, immunology, cardiology, drug discovery, and developmental biology.